Japanese researchers said Tuesday they had successfully treated monkeys with Parkinson's disease through a stem cell transplant, potentially paving the way for an ideal remedy to the intractable disease.
Their willingness also raises an ethical question: If a company stops developing a drug for safety or efficacy reasons, is it obligated to continue supplying it to patients from its clinical trials?
Some 66.4 percent of the voters said yes to the legislation which will allow scientists to study stem cells from unwanted embryos but strictly prohibit any forms of human cloning.
